Phase I trial of stereotactic body radiotherapy with concurrent fixed dose tyrosine kinase inhibitors in metastatic renal carcinoma : dose limiting toxicity and abscopal effect

01 January 2015 → 31 December 2016
Funding by bilateral agreement (private and foundations)
Research disciplines
  • Medical and health sciences
    • Morphological sciences
    • Oncology
    • Morphological sciences
    • Oncology
    • Morphological sciences
    • Oncology
tyrosine kinase inhibitors
Project description

Patients with kidney cancer that has spread, are often treated with the tyrosine kinase inhibitor substance (TKR). This substance acts targeted by the growth of the tumor cells and the blood vessels to the tumor to slow down. This treatment often works only temporarily, and some patients do not respond to. The aim of the study is to investigate whether the effect of TKR is stronger in combination with a highly-oriented (= stereotactic) radiation therapy against metastases. The advantage of this targeted radiotherapy is that the surrounding, healthy body tissues are damaged less. Moreover, it was shown that this form of radiation therapy can boost the immune system so that the tumor can attack efficiently. This technique combined with TKR, hopes the team of Professor Ost more people will respond favorably to treatment. The study will first consider whether this combined treatment is not toxic to the patient, and secondly assess the effect on metastasis.